SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
INO - Inovio Pharmaceuticals - A NYSE Small-Cap
An SI Board Since September 2012
Posts SubjectMarks Bans Symbol
67 12 0 INO
Emcee:  Lynn Type:  Moderated
Introduction Market Data Compact
Inovio is developing synthetic vaccines to prevent and treat cancers and infectious diseases. Our SynCon vaccines are designed to universally protect against unmatched, rapidly mutating viruses or break tolerance against cancers, and cannot cause the disease. Human studies have demonstrated best-in-class immune responses, surpassing conventional vaccine and other experimental immune stimulating technologies.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
67 This Company Boasted to Trump About Its Covid-19 Vaccine. Experts Are SkepticGlenn Petersen-8/9/2020
66Phase one Covid vacc trial started today ir.inovio.com INOVIO Initiates Phase 1Savant-4/6/2020
65Really interesting. Does Glaxo know?mattstat-2/28/2019
64Inovio spinoff developing patient-specific cancer therapies raises $10.5M bizjodonpat-2/28/2019
63INO getting CRUSHED after hours on toxic financing deal! TOO FUNNY!!!!! How arvitar-2/13/2019
62Inovio’s Ebola Vaccine Provides 100% Protection And Elicits Long-Lasting Immune donpat-10/15/2018
61Major Cancer Journal Highlights Data From An Inovio-Sponsored Trial In Which A Pdonpat-10/2/2018
60Inovio develops H3N2 Influenza DNA vaccine Sep. 17, 2018 9:17 AM ET By: MamtaLynn-9/17/2018
59Edited Transcript of INO earnings conference call or presentation 7-Aug-18 8:30pLynn-9/14/2018
58Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth Zacks Equity ReseaLynn-9/11/2018
57Why Inovio Pharmaceuticals Inc. Stock Bolted Higher in August George Budwell, TLynn-9/7/2018
56Inovio Doses 1st Subject in Phase 1/2 Clinical Trial For Vaccine Against Deadly Lynn-9/5/2018
55Inovio and Korean Partner Dose 1st Subject In Trial to Develop World’s First VacLynn19/4/2018
54Inovio Pharmaceuticals Initiates Dosing in HIV Vaccine Study Zacks Equity ReseaLynn-8/24/2018
53Inovio teams up with AIDS Malignancy Consortium for immunotherapy study [graphdonpat-8/6/2018
52From the end of June: Inovio Pharma announced positive Phase 1 data for vaccine Lynn-7/13/2018
51Is Inovio Pharmaceuticals, Inc. a Buy?Keith Speights, The Motley Fool July 8, 20Lynn-7/9/2018
50[graphic]arvitar-6/27/2018
49Inovio Announces Treatment of First Patient in Immuno-Oncology Study for GlioblLynn-6/21/2018
48"The lowdown is that analysts think that VGX-3100 can generate a healthy $6donpat-6/21/2018
47Are These 2 Dark Horse Vaccine Makers Worth the Risk? George Budwell, The MotleLynn-6/21/2018
46OT re Twitter: I only took a look at one person's postings, recommended by aLynn-6/13/2018
45I actually find Twitter is for twits!! I find Google answers most questions. Bdonpat-6/13/2018
44So that twitter information posted by someone on 10 May, which has in it "yLynn-6/13/2018
43Google: ir.inovio.comdonpat-6/13/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News